Result of AGM
RNS & Investor News
20 January 2016
OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it will be holding a presentation for investors on Tuesday, 16th February 2016.
The event will be held in the Black Bar, upstairs at Rocket Bar, 6 Adams Court, Old Broad Street, London EC2N 1DX from 4.30pm for a 4.45pm start.
A presentation will be given by founder & CEO of OptiBiotix, Stephen O'Hara, for approximately one hour. The presentation will include an overview of the Company, where they are currently positioned and their plans for the future. This will be followed by light refreshments and an opportunity to network.
To register for the event, please email [email protected] or call the Walbrook PR team below.
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
|Tel: 020 7148 7900|
|Hybridan LLP (Joint Broker)
Claire Louise Noyce
|Tel: 020 3713 4581|
|Peterhouse Corporate Finance Ltd (Joint Broker)
Lucy Williams / Duncan Vasey
|Tel: 020 7469 0936|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020